Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
about
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchClassical mathematical models for description and prediction of experimental tumor growthProposal of a hybrid approach for tumor progression and tumor-induced angiogenesisLifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsModel-Based Tumor Growth Dynamics and Therapy Response in a Mouse Model of De Novo CarcinogenesisModeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic DrugsPharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsDifferential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisA review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.BGFit: management and automated fitting of biological growth curvesSystems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjectsInterpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsEvolutionary dynamics of feedback escape and the development of stem-cell-driven cancers.A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid SystemsOxygen-Driven Tumour Growth Model: A Pathology-Relevant Mathematical Approach.Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsDynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapiesMechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancerPharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsPreclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma.Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacyTranslational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaCell killing and resistance in pre-operative breast cancer chemotherapyTranslational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.Modeling NSCLC progression: recent advances and opportunities availableMathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesDevelopment of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemiaAurora kinase inhibitors: identification and preclinical validation of their biomarkers.A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
P2860
Q26797238-F4EC736B-39AE-4D89-90C8-204A1729D97FQ27024682-300AA509-2C15-4E72-A283-1F19AA4381A1Q27321175-59CE60B0-8A54-4237-80ED-194ACE242EEBQ28084050-2576D96D-BFC4-4B73-98D1-4F8A68E94C12Q28543966-D1B0AC6E-15E3-42FB-AA06-43DD542CE1F6Q28551454-7D13C977-B8A2-43B1-9FEA-A7E7FACD31CCQ31143294-3D347290-D061-4A73-BB93-3344BA0C8D92Q33425648-AB782CC7-4863-4341-A3FE-8F0065D64D1EQ33551899-3DAD480A-91B1-4F2C-8052-32B2A58520E2Q33611516-0792BD5F-3227-4C29-81AC-C121482E25F9Q33613579-3D9076F8-A2CD-446F-97DC-427B66D84D4FQ33618582-54CD2444-B431-4193-A196-2994898C5E18Q33729213-85262A48-A6C8-4DA2-BF84-B897EA23CEA1Q33809839-60945F84-F0A6-45E1-AF59-DC1955EF921AQ34538416-379B98F1-6E86-46D6-8FE0-34DAEB34245FQ34901140-6C78A2FD-29BA-4513-B8D4-1EF05D8A1D9DQ34997794-D0061C48-A58F-4561-BFE0-858EDEC3E13BQ35104052-74B18CE7-A773-4134-B56D-75DB717AE6E7Q35132886-8F0F7D23-1160-41F3-B7BC-0116B47B1220Q35226129-A6365581-D591-49B6-A888-668C1813070CQ35571371-0A0417F8-171D-4326-BB27-92BB0742E60CQ35817902-E03567B1-64A6-4D75-9F12-7CF9E73E529BQ35827458-D9496C66-1604-4582-BB2A-039E85933AC3Q35827602-12C5DBEE-522C-44BD-9840-CAE6EAA3EA17Q35919697-4760F0CF-DA90-46ED-841C-D34779083196Q35987437-EFFE9A37-275C-4610-B0AC-1D74F40F2067Q36094941-75126C29-EECF-433C-9FB1-268272458AD9Q36366424-D55D724C-0EC0-42EF-BCA9-4E5109A2162FQ36402296-799EDD7C-1E02-4FFB-B480-1D9F90A00CEFQ36447737-3A7EA143-EB82-45E9-B271-0BA1B9CD6645Q36473115-79182885-BC39-4C7B-9C5C-953CDE32BF28Q36497582-FA5F3100-571E-46FC-A864-80DC2AF759B5Q36805228-BD2EDC01-A161-482B-AF24-7129BB142695Q36812607-DA7C32C7-3C23-48DA-AAB2-77F7CFDC200BQ36910546-5B321BAA-C0AA-4F19-AB8F-93BEEC793D1CQ36910615-FBB19481-A105-4CF2-B58B-9CA2C8B7AF1CQ36951914-D3166BE4-8AF9-41E6-BA6B-6A224EB16F25Q36951941-C308D123-5190-42F4-B750-37F87238F8F4Q37030878-9FE6C748-2BBC-4936-AFEF-810F79144EA1Q37034317-E8ACF4BC-FAE3-4A06-A941-A8BDEB81DAAA
P2860
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Predictive pharmacokinetic-pha ...... stration of anticancer agents.
@en
type
label
Predictive pharmacokinetic-pha ...... stration of anticancer agents.
@en
prefLabel
Predictive pharmacokinetic-pha ...... stration of anticancer agents.
@en
P2093
P1433
P1476
Predictive pharmacokinetic-pha ...... stration of anticancer agents.
@en
P2093
Cristiano Cammia
Enrico Pesenti
Giuseppe De Nicolao
Italo Poggesi
Massimiliano Germani
Maurizio Rocchetti
Monica Simeoni
Valter Croci
P304
P356
10.1158/0008-5472.CAN-03-2524
P407
P50
P577
2004-02-01T00:00:00Z